Kostas Biliouris, an analyst from BMO Capital, maintained the Buy rating on Dyne Therapeutics. The associated price target remains the same with $50.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Dyne Therapeutics’ potential in the treatment of neuromuscular disorders. The company’s strategic focus on precision muscle and CNS delivery through TfR1 Fab conjugation positions it well in the market. Dyne Therapeutics is advancing its DYNE-101 program for DM1, which currently lacks approved treatments, and is on track with its regulatory pathway, potentially offering a differentiated CNS benefit.
Furthermore, the DYNE-251 program for DMD, specifically targeting exon 51 skipping, addresses a significant unmet need, particularly for patients ineligible for existing gene therapies. The company’s financial stability, with a cash runway extending into the third quarter of 2027, supports its ongoing and future clinical trials, including the DYNE-302 program for FSHD. This diversified pipeline, coupled with recent financing and strategic trial designs, underpins the positive outlook and Buy rating assigned by Biliouris.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $50.00 price target.
DYN’s price has also changed moderately for the past six months – from $13.540 to $9.200, which is a -32.05% drop .